Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Check out some of our latest original content that was created and distributed as part of our ongoing collaborations with IR firms and other companies.

MissionIRNewsBreaks – FingerMotion Inc. (NASDAQ: FNGR) Announces Agreements to Add Charging Terminal Access for Users of Growing Da Ge App

FingerMotion (NASDAQ: FNGR), a mobile services and data company, through its contractually controlled entity, Shanghai JiuGe Information Technology Co. Ltd., is facilitating the expanded use of the Da Ge app. According to the announcement, the company is entering into arrangements with certain electric vehicle (“EV”) charging station providers in China that will allow owners of electric vehicles who have subscribed to the Da Ge app to locate and charge their cars. The arrangements are with Jiangsu YKC and Shanghai Anyo Charging Technology Co. Ltd, which operates more than 400,000 charging terminals for electric vehicles. According to the announcement, the Da Ge app will integrate with both Jiangsu YKC and Anyo Charging apps, allowing Da Ge users to access direct connections at these terminals; the agreement should provide Da Ge access to the growing Chinese EV market. FingerMotion launched the Da Ge app earlier this year. The app, which currently has 650,000 subscribers, is designed to connect subscribers with independent service stations providing car washing, fine car detailing, paint protective films, color changing and maintenance; so far 20,000 car-care service stations have been onboarded with the app with increased numbers projected by the end of the year. “We are excited to collaborate with both Jiangsu YKC and Anyo Charging and believe this will be a very positive mutually beneficial arrangement,” said FingerMotion CEO Martin Shen in the press release. “This is a big step in further monetizing our Da Ge app and giving our subscribers a product that really facilitates the use of electric charging stations in major cities across China. . . . Future Da Ge product offerings may include the company’s Top Up and Recharge service, car accessories, and possibly health and auto insurance, which could double our total subscriber numbers by FY 2026.”

To view the full press release, visit https://ibn.fm/pckpm

About FingerMotion Inc.

FingerMotion is an evolving technology company with a core competency in mobile payment and recharge platform solutions in China. As the user base of its primary business continues to grow, the company is developing additional value-added technologies to market to its users. The vision of the company is to rapidly grow the user base through organic means and have this growth develop into an ecosystem of users with high engagement rates utilizing its innovative applications. Developing a highly engaged ecosystem of users would strategically position the company to onboard larger customer bases. FingerMotion eventually hopes to serve more than 1 billion users in the China market and expand the model to other regional markets. For more information about the company, please visit www.FingerMotion.com.

NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in FingerMotion Inc. FNGR, Small Cap News | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Approval to Commence Human Pilot Study Evaluating GLP-1, DehydraTECH

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has received approval to begin a new human pilot study. The approval, which was granted by an independent third-party ethics review board, enables Lexaria to move forward with its plan to conduct a GLP-1 study investigating GLP-1 drugs and DehydraTECH(TM). According to the announcement, subject recruitment will begin immediately with the first dosing expected within the next month; the company plans to complete the study this summer. The study will be comprised of two study arms and will include up to nine healthy volunteers. The study is designed to compare a single 7 mg dose of Rybelsus(R) (semaglutide) against two different, concentration-matched 7 mg DehydraTECH-enabled semaglutide formulations from crushed Rybelsus. “I am excited about this study,” said Lexaria CEO Chris Bunka in the press release. “The Lexaria scientific team believes that a dissolvable oral tablet that delivers an effective fraction of semaglutide along with reduced side effects could potentially offer valuable benefits to the pharmaceutical industry that might lead to a higher likelihood of favorable strategic partnering with leading industry players in GLP-1. Most GLP-1 drugs sold today are administered by painful and expensive injection devices. More effective and tolerable oral delivery of GLP-1 drugs could be extremely valuable to patients and to industry.”

To view the full press release, visit https://ibn.fm/vCsqn

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery formulation and processing platform technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 41 patents granted and many patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports on Promising Results from Study on INM-089 Treatment of Dry AMD

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on additional preclinical data for INM-089, a proprietary small molecule compound acting as a preferential signaling ligand of cannabinoid receptor 1 (“CB1”) and cannabinoid receptor 2 (“CB2”). The reported data continues to demonstrate positive pharmacological effects in the treatment of dry age-related macular degeneration (“AMD”). According to the announcement, in vivo preclinical studies in AMD disease models show that INM-089 delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement. Earlier results showed that INM-089 also preserved retinal function and improved the thickness of the outer nuclear layer of the retina, where photoreceptors are located. “We are very excited with the data from recent preclinical studies demonstrating both significant functional and pathological improvements from INM-089 in the AMD model,” said InMed Pharmaceuticals SVP of preclinical research and development Dr. Eric Hsu in the press release. “While a few treatment options are currently available, their efficacy is limited and may be associated with several undesirable side effects. We see an opportunity for INM-089 to slow the progression and to fill a significant gap in the treatment of this chronic disease.”

To view the full press release, visit https://ibn.fm/jj4pN

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. The company is a clinical-stage company developing a pipeline of proprietary cannabinoid-analog therapeutics and dedicated to delivering new treatment alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, please visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

MissionIRNewsBreaks – SUIC Worldwide Holdings Ltd. (SUIC), I.Hart Group Ink Franchise Authorizations with MONGA Fried Chicken

SUIC Worldwide Holdings (OTC: SUIC), a publicly traded technology company, and its I.Hart Group Taiwan Ltd. have signed a franchise authorization with MONGA(C) Fried Chicken in Japan and in China’s Shandong Province. This is a key step as SUIC and I.Hart evaluate additional high-growth markets in Asia, which offers the largest long-term growth opportunity in the global food industry. According to the announcement, Shandong plans to open 10 stores in the first year and 300 stores within the following five years; the franchise authorizations also increase the companies’ presence across 11 countries. With these additions, SUIC and I.Hart Group will have a total of 200 stores this year and more than 500 stores over the next five years. In Shandong, which is the second-largest province in China, the franchise authorizations include 16 cities; the franchise authorizations in Tokyo also include surrounding satellite cities, with a population of 38 million people, making it the largest metropolitan area in the world. “SUIC is the biggest investor, shareholder and major operating partner of Beneway USA,” said SUIC Worldwide Holdings CEO Hank Wang in the press release. “We dedicate our team and resources to the success and expansion of our franchise development efforts and global transformation journey. We will continue to increase this momentum in 2024 and find opportunities in serving more customers around the world, growing our footprint in the global food market by tenfold.”

To view the full press release, visit https://ibn.fm/ZGoOH

About SUIC Worldwide Holdings Ltd.

SUIC Worldwide Holdings provides research and development along with venture financing for and investing in private enterprises and the public sector that develop products and services adopting core capabilities of the Internet of Things, cloud computing, mobile payment, big data, blockchain and artificial intelligence, to enhance and streamline existing processes, and establish new and exciting business models that will create revolutionary products and services. Shareholders of SUIC will be exposed to the diverse application of advanced services in various parts of the economy. Additionally, existing and potential customers can benefit from the company’s diversified portfolio of technologies. As one of the pioneering publicly traded technology companies, SUIC will help build tech-enabled businesses of the future. For more information, please visit www.SINOUnitedco.com.

NOTE TO INVESTORS: The latest news and updates relating to SUIC are available in the company’s newsroom at https://ibn.fm/SUIC

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in SUIC Worldwide Holdings Ltd. SUIC | Leave a comment

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Global Patent Portfolio to 41; Maintains Focus on GLP-1 Clinical Studies for 2024

  • Lexaria, a global innovator in drug delivery platforms, has added three new patents to its portfolio, bringing the total to 41
  • Two patents were awarded in the U.S., while the third was awarded in Japan, expiring in 2042 and 2041, respectively, if not extended
  • Lexaria’s management plans to maintain focus on GLP-1 studies for 2024

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, in the month of April 2024, added three new patents to its portfolio. This brings the total number of awarded patents globally to 41, a testament to the versatility of its patented DehydraTECH(TM) technology and its overall viability in the potential treatment of various ailments including, but not limited to, diabetes, weight loss and hypertension.

Two newly granted patents were awarded in the U.S. They fall under Lexaria’s patent family #24: Compositions and Methods for Treating Epilepsy. These two patents complement earlier research that discovered DehydraTECH-CBD was capable of mitigating epileptic seizures in animals, and was also absorbed into the bloodstream more effectively than the commercially available CBD-based anti-seizure medication, Epidiolex(R).

The third patent was granted in Japan under Lexaria’s patent family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents. This patent followed Lexaria’s demonstration of a 42%-204% improved delivery of antiviral drugs, as evidenced in numerous animal studies over the years. The first two patents will expire in 2042, while the last one will expire in 2041 if both are not extended.

These three additions bolster Lexaria’s intellectual property, which remains significant in supporting future business objectives. They are also integral in growing the company’s shareholder value, an avenue it seeks to pursue even further as time progresses. Even so, Lexaria is still committed to focusing on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year, having shown positive results in an 8-week clinical study in 2023. At the start, the company’s foray into GLP-1 studies was considered a “high-risk” program, according to the CEO, Chris Bunka. This mainly stemmed from the fact that this was a class of drugs considered “large molecules,” a class that Lexaria had never explored before, given its focus on “small molecules” (https://ibn.fm/XbnkN).

Despite the challenges and concerns, Lexaria’s GLP-1 study was a huge success that aligned with the rising interest in GLP-1 drugs owing to their health benefits. As such, the company looks to concentrate on these studies, even as it grows its intellectual property globally.

“Our R&D plans for 2024 are very tightly focused and will be concentrated mainly on GLP-1 investigations. We are not at this time planning additional 2024 research in the antiviral nicotine, or PDE5 sectors. We have solid early-stage data in each of those areas that will allow us to build upon those at the right time,” noted Mr. Bunka.

GLP-1 studies will run alongside international patent applications. Upcoming patents are expected to cover swallowed capsules and dissolvable oral tablets. Lexaria’s management is confident in its current direction and maintains that 2024 will be the year the company’s hard work will prove itself. It is a testament to its commitment to creating shareholder value and asserting itself as a leader in its space.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Represents Opportunity to Provide Solution for GBM Patients

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biopharmaceutical company advancing its lead drug candidate, Berubicin, along the pathway to potential regulatory approval and commercialization, recently appointed Amy Mahery to its board of directors. “A biotech commercialization leader, Ms. Mahery has built an illustrious career that spans more than 20 years. During this period, she has gained commercial expertise working with small and large companies in common and rare conditions, as well as across several therapeutic areas… Ms. Mahery lauded CNS Pharmaceuticals and its efforts to fill gaps in areas with high unmet medical needs, such as glioblastoma multiforme (‘GBM’) treatment, saying, ‘I have been intrigued by the company’s pivotal trial design for Berubicin and was further compelled by the successful outcome from the recent interim analysis, the rapid pace of enrollment, and strong management team,’” a recent article reads. “Ms. Mahery believes Berubicin represents an opportunity to provide a solution for patients with GBM, the most aggressive type of brain cancer. Berubicin, an anthracycline, appears to cross the blood-brain barrier and kill cancer cells, as results from the completed Phase 1 human clinical trial show. The trial demonstrated positive responses that included one durable complete response.”

To view the full article, visit https://ibn.fm/IUE8R

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

SuperCom Ltd. (NASDAQ: SPCB) Confident in its EM Solutions’ Adoption Given Growing Reception and Demonstrated Advantages

  • SuperCom, a global leading provider of traditional and digital identity solutions, recognizes the growing domestic violence (“DV”) cases and looks to remedy it through its innovative electronic monitoring (“EM”) solutions
  • DV cases in the US have posted an unfortunate 8.7% growth since 2019, primarily attributed to the lack of accountability and the overall lack of proactivity from law enforcement in dealing with offenders
  • With incarcerations having proven ineffective in reducing these numbers, there has been a move toward EM adoption, which, with the right technologies, has yielded impressive results

SuperCom (NASDAQ: SPCB), a global leading provider of traditional and digital identity solutions offering advanced safety, identification, and security products and solutions to governments, is aware of the growing domestic violence cases and believes it has the technology to help remedy the situation. So far, its electronic monitoring (“EM”) solutions have proven themselves in monitoring and holding domestic violence offenders accountable for their actions in a variety of markets, including the U.S.

According to the comptroller’s office, domestic violence (“DV”) cases in the U.S. have grown by 8.7% since 2019, with one in four women and one in 10 men have experienced domestic violence to some sort of degree in their lifetime. This growth has been attributed to the lack of accountability, particularly for offenders, and an overall lack of proactivity from law enforcement in dealing with the situation. This lack of consequences has seen more people emboldened to commit domestic violence offenses, an issue that is slowly getting out of hand (https://ibn.fm/RDhjc).

While there has been a push for the incarceration of DV offenders, the move has been largely ineffective. In a study conducted by the Bureau of Crime Statistics and Research (“BOACAR”), it was noted that prison time does not deter domestic violence offenders any more than a suspended sentence. The study, which compared 1,612 matched pairs of DV offenders, showed that after one year in the community, 20.3% of people given a suspended sentence and 20.3% of people given a prison sentence had at least one new DV-related offense. The difference was slightly more pronounced after three years in the community, where the former stood at 34.2% while the latter stood at 32.3% (https://ibn.fm/C00kZ).

Another study published by the IZA Institute of Labor Economics noted that electronic monitoring reduced reoffending within 24 months by 16% compared to serving a prison sentence. In addition, the study established that for offenders under 30 years, the reduction was 43%, with sizable and significant reductions in reoffending persisting for eight years (https://ibn.fm/sxoXM).

Incarceration has proven to be ineffective in reducing recidivism and in reducing DV cases. In addition, there has been a push and a preference by DV survivors not to have the offenders sent to jail for a variety of reasons, the main one of which is financial. SuperCom understands these dynamics and proactively pushes for its EM solutions, ultimately growing its market share and customer numbers. With the reception it has gotten so far, along with the results its EM solutions have shown, the company is confident that it can help address the growing DV cases globally.

“[Our] innovative tools are designed to provide law enforcement and criminal justice agencies with real-time data and analytics, helping prevent tragic outcomes by ensuring constant monitoring and swift response in critical situations,” noted a post on SuperCom’s LinkedIn page.

“SuperCom’s technology demonstrates a commitment to public safety and the protection of vulnerable individuals, aligning closely with the heightened need for effective and proactive measures in domestic violence cases,” it further noted (https://ibn.fm/2W9Er).

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in SuperCom Ltd. SPCB | Leave a comment

Distributed Energy Solutions Provider Correlate Energy Corp. (CIPI) Accelerates Green Energy Momentum with Efficient & Affordable Technologies, Scalable Business Model

  • Climate impact concerns are a defining issue, not only in the U.S. but around the world, with a new generation of innovators seeking to learn from past mistakes and better address the need for clean energy solutions
  • Distributed energy solutions company Correlate Energy Corp. is successfully focusing on the most cost effective and efficient solar energy installation opportunities and clean energy infrastructure optimization
  • As part of this, the company is also optimizing a renewable revenue stream by carefully retaining ownership of some of its energy systems while acquiring other renewable energy companies with proven capabilities
  • The company’s average contract size is now about $2 million, and CIPI currently has about $150 million in-progress projects in various stages of development

Planetary climate change is increasingly viewed as the single most over-arching technological issue in need of a worldwide solution, but efforts to innovate and advance solutions are hampered by the need for cost-effective and workable startup-enterprise financing models.

In spite of initial challenges and missteps, progress is accelerating in the development of viable green solutions and associated business and financial models. In his analysis on innovation, Forbes Technology Council member Steve Smith recently argued that business investment in “this transformative field” must be more responsive to real-world conditions, such as the intermittent availability of wind and solar power sources, the imbalance between peak user demand and peak energy-generation, and the need to ensure that potential customers are motivated (https://ibn.fm/OPjYe).

Distributed energy solutions company Correlate Energy (OTCQB: CIPI) is advancing its superior cost-effective solutions for making solar power and other green energy solutions accessible from the ground up — working with baseline consumers and mid-tier companies that are often overlooked by larger forces in the sustainability market. Most of the company’s clients have portfolios with dozens of locations across the country that may need Correlate’s services.

Because many concerns regarding energy use revolve around site-specific buildings, Correlate Energy’s has focused on retrofitting existing commercial buildings with renewable energy solutions that improve a company’s carbon footprint and make overall energy consumption more efficient, while also ensuring financial arrangements that make the whole process eminently affordable.

Correlate Energy is moving to identify localized green energy solutions and microgrids that it can strategically finance, develop, and profitably sell to its customers, while also positioning itself to retain ownership of some of its energy systems and acquire other renewable energy companies with proven capabilities, allowing Correlate to scale its operations vertically for consistent revenue streams.

“We have a constant conveyor belt of a maturity of opportunities which allow us to smartly invest in different parts of the business,” Correlate Energy President and CEO Todd Michaels stated recently (https://ibn.fm/r8tMl).

“We have about $150 million of immediately actual projects that are (in) various stages of … development,” Michaels said in December (https://ibn.fm/OMJ3u). “About $22 million of those are, currently like, people are literally out there deployed onsite getting these projects completed. We have about another $50 million of projects that are fully contracted, that are mobilizing — they’re typically waiting for a utility approval, some permit, or are waiting for next summer to build versus building them in a place where we might be doing wintertime issues. So those are kind of the ready-to-go projects.”

Projects completed or newly announced in recent months include an up-to-40 MW Southern California microgrid project for a customer representing one of the state’s largest privately owned oil and gas corporations, a 5.2 MW solar energy installation project for a Pennsylvania-based stored energy solutions company, and rooftop solar energy systems for companies in North Carolina and Illinois.

For more information, visit the company’s website at www.Correlate.Energy, including the following:

Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.Correlate.Energy/our-process
Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.Correlate.Energy/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Correlate Infrastructure Partners Inc. CIPI | Leave a comment

Zoned Properties Inc. (ZDPY) Releases Positive FY2024 Annual Results Amid U.S. Cannabis Industry Boom

  • There are more cannabis dispensaries than McDonald’s outlets in the United States today, a reflection of the ongoing shift in consumer trends and legal frameworks across America
  • Over 74% of Americans now live in a state which permits either, the medical or recreational consumption of marijuana
  • Zoned Properties has emerged as an early leader in facilitating the transition of U.S. cannabis businesses towards developing a physical retail footprint with a portfolio of cannabis-focused investment properties across Arizona, Michigan and Illinois
  • The company recently updated the market with the release of a positive set of FY 2023 annual results

In 2019, McDonald’s launched a nationwide marketing campaign across the nation entitled, ‘Around the world is now around the corner’ (https://cnw.fm/BrsKg). Celebrating the fact that some of the chain’s most popular global offerings were now easily found in everyone’s local participating McDonald’s, the campaign hinged on the seemingly ubiquitous availability and presence of the restaurant’s outlets across the United States. Remarkably and in representation of America’s rapidly changing attitude towards cannabis today, the number of cannabis dispensaries dotted across the United States have now surpassed those of McDonald’s Corp restaurants, a reflection of the United States’ dramatic and ongoing evolution in consumer trends and legal frameworks.

A recent study by the Pew Research Center have revealed that over half of Americans now live in areas permitting recreational cannabis use, a statistic made even more noteworthy as it comes only twelve years after Colorado and Washington led a landmark decision towards legalizing marijuana usage. Meanwhile, 74 percent of Americans reside in states where marijuana use, whether for recreational or medical purposes, is now legal – a shift which has driven to the establishment of nearly 15,000 cannabis dispensaries nationwide (https://cnw.fm/vpqax).

“It’s all about location and good capitalization” explained Joe Lustberg, managing partner at Upwise Capital, which has been amongst the pioneers in financing the United States’ burgeoning cannabis industry. Retail has rapidly emerged as an essential sales vertical within the cannabis ecosystem, with cultivators and processors alike seeking viable outlets for their products.

Zoned Properties (OTCQB: ZDPY), a technology-driven property investment company focused on acquiring value-add real estate within the regulated cannabis industry in the United States, has been amongst the early leaders in facilitating the transition of the cannabis industry towards the physical retail space. The company maintains a portfolio of six investment properties located across Arizona, Michigan and Illinois; with each of its leased properties occupied by commercial cannabis-linked businesses, the company currently enjoys a 100% occupancy rate with a weighted average lease term of over 10 years. In addition to maintaining four properties leased and repurposed as regulated cannabis retail dispensaries, the company presently leases two properties which are operated as regulated cannabis cultivation and processing facilities.

Zoned Properties recently updated the market following the release of their annual financial results for 2023 (https://cnw.fm/Mobyi). The company revealed that top-line revenues had grown to $2.89 million in FY2023, representing an increase of 8.5 percent relative to the previous year. Meanwhile, operating expenses had marginally declined to $2.72 million compared to $2.77 million in FY2022, a year-over-year decrease of 1.9%. Zoned Properties also announced that its net losses had narrowed to $540,248 for the 2023 fiscal year, down from $574,355 the prior year.

Additionally, the company revealed that its operational results had enjoyed a marked acceleration in the latter half of the year, with fourth quarter 2023 revenues rising by 16.2 percent year over year with quarterly losses decreasing by -10.4 percent relative to the fourth quarter of 2022.

“As we reflect on our Full Year 2023 results and our recent strategic updates, it’s clear that Zoned Properties is firmly on a trajectory of sustainable growth and value creation,” said Bryan McLaren, Chief Executive Officer of Zoned Properties.

Furthermore, McLaren elaborated on the company’s decision to list its cultivation property located in Arizona’s Chino Valley for sale at a purchase price of $16 million; the proposed sale forms part of Zoned Properties’ ongoing move towards refocusing its efforts towards its core direct-to-consumer property assets, a shift which has seen the company recently acquire a further two investment properties for use as potential dispensary sites.

“The listing of our Chino Valley property is an important step unlocking the potential opportunity to raise significant non-dilutive capital and reflects our commitment to seizing market opportunities with a dedication to enhancing shareholder value,” he continued. “Our journey is guided by a clear vision: to utilize our property technology competitive advantages to drive scale and innovate within our industry, delivering tangible, long-term value to our shareholders. We’re excited about what the future holds and remain dedicated to our strategic growth path, and operational excellence as we move forward.”

For more information, visit the company’s website at www.ZonedProperties.com.

NOTE TO INVESTORS: The latest news and updates relating to ZDPY are available in the company’s newsroom at https://cnw.fm/ZDPY

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Zoned Properties Inc. ZDPY | Leave a comment

MissionIRNewsBreaks – Zoned Properties Inc. (ZDPY) Continues to Align with Evolving Cannabis Market

Zoned Properties (OTCQB: ZDPY), a technology-driven property investment company for emerging and highly regulated industries, is focusing on seizing direct-to-consumer real estate opportunities in the rapidly growing and regulated cannabis market. This is amid changing regulations and attitudes towards cannabis use, which are transforming the industry. “Cannabis businesses are expanding significantly as regulations evolve, leading to an increased demand for specialized, direct-to-consumer properties that include dispensaries, manufacturing or processing centers, and distribution hubs. Real estate investors are capitalizing on this demand by acquiring properties for rental income generation while potentially realizing significant property value appreciation as the industry grows,” a recent article reads. “In alignment with the evolving market, ZDPY has recently secured and acquired investment properties in Michigan, Arizona and Illinois. All properties in ZDPY’s portfolio boast 100% occupancy and a weighted average lease term of 10+ years. Each leased property is occupied by a commercial cannabis tenant, and the company anticipates more than $2.5 million from its property investment portfolio in 2024. Zoned Properties Brokerage has closed over $80 million of commercial real estate deals nationally since 2021… ZDPY is also leveraging digital innovation through its proprietary cannabis technology platform, called REZONE. Similar endeavors have leveraged data-driven insights, analytics and artificial intelligence to identify potential investment properties, streamline processes and enhance efficiency.”

To view the full article, visit https://ibn.fm/rWH7y

About Zoned Properties Inc.

Zoned Properties is a technology driven property investment company focused on acquiring value-add real estate within the regulated cannabis industry in the United States. The company aspires to innovate within the real estate development sector, focusing on direct-to-consumer real estate that is leased to the best-in-class cannabis retailers. Headquartered in Scottsdale, Arizona, Zoned Properties is redefining the approach to commercial real estate investment through its standardized investment process backed by its proprietary property technology. Zoned Properties has developed a national ecosystem of real estate services to support its real estate development model, including a commercial real estate brokerage and a real estate advisory practice. With a decade of national experience and a team of experts devoted to the emerging cannabis industry, Zoned Properties is addressing the specific needs of a modern market in highly regulated industries. The company targets commercial properties that face unique zoning or development challenges, identifies solutions that can potentially have a major impact on their commercial value, and then works to acquire the properties while securing long-term, absolute-net leases. Zoned Properties targets commercial properties that can be acquired and rezoned for specific purposes, including the regulated and legalized cannabis industry. It does not grow, harvest, sell or distribute cannabis or any substances regulated under United States law such as the Controlled Substance Act of 1970, as amended (the “CSA”). Zoned Properties corporate headquarters are located at 8360 E. Raintree Dr., Suite 230, Scottsdale, Arizona. For more information, call 877-360-8839 or visit www.ZonedProperties.com.

NOTE TO INVESTORS: The latest news and updates relating to ZDPY are available in the company’s newsroom at https://ibn.fm/ZDPY

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Zoned Properties Inc. ZDPY | Leave a comment